21 active not recruiting, 13 recruiting, 11 completed, 4 terminated. 32 Phase 2, 25 Phase 1, 4 Phase 3, 1 Not applicable.
Follow Recurrent Lung Non-Small Cell Carcinoma: new trials by email Literature Review of Recurrent Lung Non-Small Cell Carcinoma trials Research Report on Recurrent Lung Non-Small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer Atezolizumab, CXCR1/2 Inhibitor SX-682, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | University of Washington | 32 | 2026-10-06 | 2026-10-13 |
| Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Computed Tomography, Ivonescimab - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 117 | 2026-09-22 | 2026-10-13 |
| MOv19-BBz CAR T Cells in FRa+ Cancers MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing - Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Recruiting | University of Pennsylvania | 10 | 2025-10-07 | 2026-10-07 |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Cemiplimab, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 / Phase 3 | Recruiting | SWOG Cancer Research Network | 378 | 2025-05-22 | 2026-10-09 |
| Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | Dwight Owen | 24 | 2024-12-31 | 2026-09-18 |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Computed Tomography, Lymphoscintigraphy - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 56 | 2024-08-08 | 2026-10-09 |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer Cetuximab, Osimertinib, Tucatinib - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Not yet recruiting | Jonathan Riess | 36 | 2024-01-01 | 2023-10-05 |
| OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | University of Washington | 2023-12-01 | 2023-08-25 | |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) Biospecimen Collection, Capmatinib, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 66 | 2023-05-05 | 2026-06-03 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | University of Washington | 30 | 2023-04-06 | 2026-06-17 |
| Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study Chemotherapy, Pembrolizumab, Ramucirumab - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 838 | 2023-03-14 | 2026-04-17 |
| PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, Nivolumab - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Recruiting | Dwight Owen | 30 | 2022-11-21 | 2026-02-06 |
| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Carboplatin, Pemetrexed, Selpercatinib - Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | SWOG Cancer Research Network | 2022-07-25 | 2024-07-09 | |
| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | University of California, Irvine | 6 | 2022-07-20 | 2026-10-06 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 28 | 2022-06-09 | 2026-07-22 |
| Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Cobalamin, Dexamethasone, Docetaxel - Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | SWOG Cancer Research Network | 82 | 2022-03-15 | 2026-05-18 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Tretinoin - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | Dwight Owen | 18 | 2021-10-18 | 2026-07-20 |
Showing 20 of 55. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (55) · Lung Neoplasms (41) · Adenocarcinoma of Lung (4) · Melanoma (4) · Brain Neoplasms (3) · Carcinoma, Renal Cell (3) · Neoplasm Metastasis (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Breast Neoplasms, Male (1)
Bronchial Neoplasms (55) · Carcinoma, Bronchogenic (55) · Lung Diseases (55) · Neoplasms (55) · Neoplasms by Site (55) · Respiratory Tract Diseases (55) · Respiratory Tract Neoplasms (55) · Thoracic Neoplasms (55) · Lung Neoplasms (14) · Neoplasms by Histologic Type (9) · Adenocarcinoma (7) · Carcinoma (7) · Neoplasms, Glandular and Epithelial (7) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6)
Magnetic Resonance Spectroscopy (13) · Specimen Handling (12) · pembrolizumab (8) · Pemetrexed (7) · Ramucirumab (7) · atezolizumab (7) · osimertinib (7) · Carboplatin (6) · Nivolumab (6) · Biopsy (5) · Docetaxel (5) · Disulfides (4) · Immunoglobulin G (4) · Radiation (4) · sapanisertib (4)
M.D. Anderson Cancer Center (13) · National Cancer Institute (NCI) (13) · SWOG Cancer Research Network (10) · University of Washington (5) · Dwight Owen (3) · Mayo Clinic (2) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Institut de Recherches Internationales Servier (1) · Jonathan Riess (1) · Ohio State University Comprehensive Cancer Center (1) · University of California, Irvine (1) · University of Pennsylvania (1) · Wake Forest University Health Sciences (1)
United States (54) · Canada (2) · Australia (1) · China (1) · Denmark (1) · France (1) · Guam (1) · Hong Kong (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Jonathan W Riess (5) · Yasir Y Elamin (3) · Yasir Y Elamin, MD (3) · Dwight H Owen, MD (2) · Karen L Reckamp (2) · Saumil Gandhi (2) · Aminah Jatoi, MD (1) · Andrew Haas, MD, PhD (1) · Asrar Alahmadi, MBBS, MAS-CR (1) · Chad Tang (1) · Christina Baik, MD, MPH (1) · Christina S. Baik (1) · Dev Mukhopadhyay, PhD (1) · Don L Gibbons (1) · Dwight H Owen, MD, MS, FACP (1)
PMID 27789196, PMID 27825638, PMID 29217088, PMID 31678224, PMID 34140248, PMID 34550757, PMID 35820397, PMID 37233987, PMID 37478883, PMID 38572955, PMID 39903538, PMID 40782807, PMID 40791544, PMID 41484629, PMID 42161344, PMID 42687919, PMID 42847673
U10CA180888 (11), P30CA016672 (3), U10CA180820 (3), UM1CA186717 (3), P50CA228944 (2), U01CA062461 (2), 2025 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), P01CA021239 (1), P30CA012197 (1), P30CA015704 (1), P30CA016058 (1), P30CA033572 (1)